"CareMed’s level of service has always set us apart to our patients and healthcare partners," CareMed Senior Vice President, John Witkowski said. "We will continue to provide the highest level of patient care to our Otezla patients and are excited to be an active partner with new developments in treatment for our psoriatic arthritis patients".
According to the National Psoriasis Foundation, psoriasis is the most prevalent chronic inflammatory disease in the U.S.
Otezla was approved on Mar 21, 2014, and is the first oral therapy approved for this disease state. OTEZLA is an oral small-molecule inhibitor of phosphodiesterase 4 (PDE4) specific for cyclic adenosine monophosphate (cAMP). The approval was based on safety and efficacy results from three multi-center, randomized, double-blind, placebo-controlled trials - PALACE 1, 2 and 3 - conducted in adult patients with active psoriatic arthritis who were inadequately controlled by disease-modifying anti-rheumatic drugs (DMARDs) and/or biologics.